-
-
-
-
-
-
-
Baird stays Outperform on Mereo BipPharma Group (MREO) as market eyes regulatory path for setrusumab
-
-
-
-
-
-
-
Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
-
-
-
-
-
-
Ultragenyx and Mereo advance UX143 osteogenesis imperfecta study to final analysis
-
-
-
-
-
-
-
Increasing unusual call option volume: COMM INFY XLI JACK MREO UMC MRVI BIRK ARVN
-
-
-
-
-
-
-
Baird Starts Mereo BipPharma Group (MREO) at Outperform
-
475,472 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


